Japan's Mitsubishi Tanabe files for ALS drug edaravone in U.S.

FDA sign
FDA sign

Osaka-based Mitsubishi Tanabe Pharma has moved to get U.S. FDA approval for edaravone (Radicut) to treat amyotrophic lateral sclerosis (ALS) as it moves to expand its product offerings in the key market through collaboration with partners and new a local unit.

In a release, the company said as many as 30,000 people in the U.S. suffer from the progressive neurological condition known as Lou Gehrig's disease after a famous baseball player, with an estimated 5,600 diagnosed each year.

MT Pharma America was started earlier this year as a marketing arm in the U.S. with a target date for approval in 2017 for approval of the ALS candidate.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

U.S. approval for edaravone (MCI-186) would draw on clinical data from Japan where the drug marketed as Radicut was launched around a year earlier to treat ALS patients and has been used since 2001 to treat acute cerebral infarction.

Phase III results of a study on 137 Japanese patients were presented at the American Academy of Neurology meeting in April and demonstrated less functional motor-control loss, compared to standard of care, meeting its primary endpoint.

"There is an urgent need for new treatment approaches that may affect the course of this devastating disorder," Lucie Bruijin, chief scientist of the ALS Association, said in a statement.

- here's the release

Related Article:
Mitsubishi Tanabe says ALS drug meets PhIII endpoint


Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.